Responding to the agency’s stern rebuke, Vas Narasimhan, the company’s executive, tried to reassure investors that Novartis did not intentionally deceive the F.D.A. while seeking approval for its $2.1 million gene therapy.
Published: August 7, 2019 at 02:00AM
from NYT Health https://ift.tt/2YPZ7N5